FDA is Open to the Idea of Possible Regulatory Flexibility for Cell and Gene Therapies on a Case-by-Case Basis…Where Appropriate January 13, 2026 By Richard A. Lewis, Principal Regulatory Device and Biologics Expert —

https://www.thefdalawblog.com/2026/01/fda-is-open-to-the-idea-of-possible-regulatory-flexibility-for-cell-and-gene-therapies-on-a-case-by-case-basiswhere-appropriate/?utm_source=rss&utm_medium=rss&utm_campaign=fda-is-open-to-the-idea-of-possible-regulatory-flexibility-for-cell-and-gene-therapies-on-a-case-by-case-basiswhere-appropriate Ret. DEA Chief ALJ Mulrooney and HPM’s Andrew Hull to Present at the ACI Controlled Substance Summit January 13, 2026 By Andrew J. Hull — https://www.thefdalawblog.com/2026/01/ret-dea-chief-alj-mulrooney-and-hpms-andrew-hull-to-present-at-the-aci-controlled-substance-summit/?utm_source=rss&utm_medium=rss&utm_campaign=ret-dea-chief-alj-mulrooney-and-hpms-andrew-hull-to-present-at-the-aci-controlled-substance-summit